A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome
A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
Parts 1 and 2 are randomized, placebo-controlled, single-ascending-dose (SAD) and multiple-ascending-dose (MAD) study parts, respectively, in healthy participants. Part 3 will evaluate multiple dose administrations in participants with Netherton syndrome in an open-label design. Part 4 will evaluate multiple administrations of BCX17725 in participants with Netherton syndrome in an open-label study design over 12 weeks, with an 8-week post-treatment follow-up period.
Key Inclusion Criteria:
clinicaltrials@biocryst.com+1 919 859 1302
Palo Alto, California 94304, United States
cnlee06@stanford.edu650-497-7230
tbusch@stanford.edu352-278-7603
hbailon@therapeuticsresearch.com858-571-6800 ext. 141
nicole.olszewski@yale.edu203-785-5505
NUderm-research@northwestern.edu312-503-5944
jprusa@ecommunity.com317-516-5030 ext. 108
wslhd-dermatology-clinicaltrials@health.nsw.gov.au02 8890 5686
trials@veracityclinicalresearch.com.au07 3039 1311
emilie.fapong@aphp.fr01 42 49 40 62
hafsoiti.hassandjohar@aphp.fr01 42 49 40 62
genodermatose@mumc.nl+31 (0)43-3875290